Management outlines the Company’s pipeline priorities for 2023 and provides a data update for the CX-2029 Phase 2 Cohort Expansion Study on a conference call to be held on January 5 at 5 pm. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CTMX:
- CTMX Surges after Announcing MRNA Collaboration
- CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities
- CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
- CytomX Therapeutics to host conference call
- CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023